Drugs / MPT0E028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02350868 | Apr 2015 → Jan 2019 | high grade malignant neoplasm | Taipei Medical University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-28 | J Ints Bio | ㈜조시아바이오, HDAC 억제제 신약 파이프라인 말초 T 세포 림프종 ‘MPT0E028’ 자문위원회 회의 개최 jintsbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPT0E028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02350868 ↗ |
| Route | Oral | “oral doses of MPT0E028” NCT02350868 ↗ |